F
ENvue Medical, Inc.
FEEDCIK 0001326706NasdaqNon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31
Period
FY 2025
Revenue
$2.55M
Net Income
$-18.18M
Total Assets
$41.12M
Equity
$33.50M
Shares Out
6.09M
Op. Cash Flow
$-9.37M
Business
ENvue Medical, Inc. operates two medical device divisions. ENvue Medical Holdings develops electromagnetic navigation systems for enteral feeding tube placement, offering an FDA-cleared system with proprietary single-use tubes. NanoVibronix develops non-invasive ultrasound-based devices: PainShield for pain relief and UroShield for catheter biofilm prevention. Both divisions target hospitals and clinical customers, selling directly and through group purchasing organizations and distributors in the US, EU, and other markets.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 3 | 3 | 2 | 752,000 | 2 | |
| Cost of revenues | 2 | 1 | 746,000 | 585,000 | 925,000 | |
| Gross profit | 153,000 | 2 | 2 | 167,000 | 770,000 | |
| Research and development | 2 | 909,000 | 185,000 | 283,000 | 293,000 | |
| Selling and marketing | 2 | 720,000 | 864,000 | 965,000 | 1 | |
| General and administrative | 8 | 3 | 4 | 4 | 5 | |
| Impairment of goodwill and long-lived assets | 11 | — | — | — | — | |
| Total operating expenses | 23 | 5 | 5 | 5 | 6 | |
| Loss from operations | −23 | −4 | −3 | −5 | −6 | |
| Financial income (expense), net | 4 | −104,000 | −111,000 | — | — | |
| Loss before taxes on income | −18 | −4 | −4 | −5 | −14 | |
| Income tax (expense) benefit | 307,000 | −19,000 | −29,000 | −35,000 | −32,000 | |
| Net loss | −18 | −4 | −4 | −5 | −14 | |
| Dividend on Series X Preferred Stock | −2 | — | — | — | — | |
| Dividend on Series H Preferred Stock | −396,000 | — | — | — | — | |
| Deemed dividend for down round feature on Series H Preferred Stock | −399,000 | — | — | — | — | |
| Deemed contribution on repurchase of Preferred Series X | 90,000 | — | — | — | — | |
| Deemed contribution on modification of Preferred Series X | 4 | — | — | — | — | |
| Net loss available to common stockholders | −17 | −4 | −4 | −5 | −14 | |
| Basic net loss available for holders of common stock | −26.69 | −137.3 | −23.32 | −3.84 | −11.35 | |
| Diluted net loss available for holders of common stock | −26.69 | −137.3 | −23.32 | −3.84 | — | |
| Weighted average common stock outstanding, basic | 628,534 | 26,985 | 159,105 | 1 | 1 | |
| Weighted average common stock outstanding, diluted | 628,534 | 26,985 | 159,105 | 1 | — | |
| Change in foreign currency translation adjustments | — | −13,000 | −49,000 | — | — | |
| Total Comprehensive loss | −18 | −4 | −4 | −6 | −14 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 752,000 | — | — | 8 | |
| Restricted cash | 30,000 | — | — | — | — | |
| Trade receivables | 289,000 | 98,000 | 318,000 | 9,000 | 200,000 | |
| Prepaid expenses and other accounts receivable | 391,000 | 290,000 | — | — | — | |
| Inventory | 2 | 2 | 3 | 2 | 175,000 | |
| Total current assets | 7 | 3 | 6 | 6 | 8 | |
| Property and equipment, net | 119,000 | 9,000 | 7,000 | 7,000 | 5,000 | |
| Severance pay fund | 125,000 | 173,000 | 174,000 | 179,000 | 207,000 | |
| Operating lease right-of-use assets | 127,000 | 116,000 | 5,000 | 81,000 | 49,000 | |
| Long-term trade receivables | 20,000 | — | — | — | — | |
| Intangible Assets, net | 4 | — | — | — | — | |
| Goodwill | 29 | — | — | — | — | |
| Total non-current assets | 34 | 298,000 | 187,000 | 270,000 | 280,000 | |
| Total assets | 41 | 4 | 7 | 6 | 9 | |
| Trade payables | 719,000 | 47,000 | 138,000 | 66,000 | 87,000 | |
| Arbitration liability | 2 | 2 | — | — | — | |
| Other accounts payable and accrued expenses | 2 | 491,000 | 2 | 2 | 2 | |
| Loans | 1 | — | — | — | — | |
| Deferred revenue | 175,000 | 15,000 | — | — | — | |
| Operating lease liabilities - current | 89,000 | 52,000 | 5,000 | 81,000 | 49,000 | |
| Total current liabilities | 7 | 3 | 2 | 2 | 2 | |
| Warrant liability | 807,000 | — | — | — | — | |
| Accrued severance pay | 132,000 | 216,000 | 217,000 | 223,000 | 253,000 | |
| Operating lease liabilities, non-current | 28,000 | 64,000 | — | — | — | |
| Total liabilities | 8 | 3 | 3 | 3 | 2 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2025 and December 31, 2024, respectively; Issued and outstanding: 1,100,413 and 37,894 shares at December 31, 2025 and December 31, 2024, respectively | 1,000 | 1,000 | 2,000 | 2,000 | 1,000 | |
| Additional paid in capital | 124 | 71 | 70 | 66 | 63 | |
| Accumulated other comprehensive income | −80,000 | −80,000 | −67,000 | −18,000 | 60,000 | |
| Accumulated deficit | −90 | −70 | −66 | −62 | −57 | |
| Total stockholders equity | 33 | 627,000 | 4 | 3 | 6 | |
| Total liabilities and stockholders equity | 41 | 4 | 7 | 6 | 9 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 897,000 | 1,000 | 1,000 | 1,000 | 2,000 | |
| Stock-based compensation | — | 356,000 | 293,000 | 354,000 | 382,000 | |
| Noncash interest expense | 239,000 | 100,000 | 135,000 | 347,000 | — | |
| Other | 19,000 | 1,000 | — | — | — | |
| Changes in deferred income taxes, net | −373,000 | — | — | — | — | |
| Change in fair value of warrant liability | −6 | — | — | — | — | |
| Issuance cost allocated to warrant liability | 1 | — | — | — | — | |
| Trade receivable | −179,000 | 221,000 | −309,000 | 191,000 | −175,000 | |
| Prepaid expenses and other accounts receivable | −96,000 | −136,000 | — | — | — | |
| Inventory | 249,000 | 541,000 | −557,000 | −2 | −30,000 | |
| Trade payables | 552,000 | −91,000 | 72,000 | −21,000 | −59,000 | |
| Other accounts payable and accrued expenses | 1 | 242,000 | −18,000 | 78,000 | −265,000 | |
| Deferred revenue | 160,000 | −46,000 | −67,000 | −69,000 | −2,000 | |
| Operating right of use asset | 71,000 | 34,000 | — | — | — | |
| Operating lease liabilities | −85,000 | −34,000 | — | — | — | |
| Accrued severance pay, net | −36,000 | — | −1,000 | −2,000 | — | |
| Net cash used in operating activities | −9 | −3 | −4 | −7 | −4 | |
| Cash acquired in Envue Merger | 148,000 | — | — | — | — | |
| Purchase of property plant and equipment | −60,000 | −3,000 | −1,000 | −3,000 | −3,000 | |
| Net cash provided by (used in) investing activities | 88,000 | −3,000 | −1,000 | −3,000 | −3,000 | |
| Proceeds from the issuance of common stock, preferred stock and warrants, net | 19 | — | — | — | — | |
| Repurchase of Series X Preferred Stock | −5 | — | — | — | — | |
| Proceeds from issuance of notes payable to related party | 1 | — | — | — | — | |
| Payments of note payable to related party | −1 | — | — | — | — | |
| Payments of short-term loan to related party | −2 | — | — | — | — | |
| Proceeds from issuance of short-term loan payable | 360,000 | — | — | — | — | |
| Proceeds from exercise of warrants | 102,000 | 1,000 | 7,000 | 2,000 | — | |
| Other | 12,000 | — | — | — | — | |
| Net cash provided by financing activities | 13 | 1,000 | 4 | 2 | 5 | |
| Effects of currency translation on cash and cash equivalents | — | −13,000 | −49,000 | −78,000 | −6,000 | |
| Net increase in cash, cash equivalents and restricted cash | 4 | −3 | 570,000 | −5 | 204,000 | |
| Cash paid for interest | 25,000 | — | — | — | — | |
| Cash paid for taxes | 52,000 | — | — | — | — | |
| Right of use asset obtained in the exchange for operating lease liabilities | 24,000 | 145,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is ENvue Medical, Inc.'s CIK number?
ENvue Medical, Inc.'s SEC CIK number is 0001326706 (1326706). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ENvue Medical, Inc.'s SEC filings?
All of ENvue Medical, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.